To assess the relative contribution of TOX as chromatin modifier in CNS autoimmunity or after acutely resolved infection, we plotted the chromatin accessibility of ChARs that varied in absence of TOX in AL and VL (Log2 FC ≥ 1; FDR < 0.05) (Fig. 4d and Supplementary data 6: TOX-dependent chromatin accessibility changes in AL and VL). The gene discussed is TOX; the disease is Autoimmunity.